New research reveals that patients who stop using popular GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds far faster than those who end conventional diet and exercise regimens.
Research printed in a major health publication demonstrates that while overweight individuals can lose a large proportion of their total mass while undergoing treatment, the weight comes back at an average rate of nearly a kilo each month upon discontinuation.
"Individuals purchasing such drugs must be aware of the risk of rapid rebound weight gain when the therapy is stopped," warns expert Dr. Susan Jebb.
This pace of regain suggests a return to original weight within about a year and a half.
Weighing Approaches
The research, which examined dozens of trials involving thousands of participants, compared the results of these new drugs with other pills.
Researchers emphasize that individuals who lose weight through diet and exercise usually experience a slower weight regain—perhaps 100 grams monthly—once they finish.
The Reason for the Fast Regain
Experts propose the way of the drugs accounts for the accelerated rebound.
These medications mimic a natural hormone called GLP-1, which controls hunger.
"Artificially providing GLP-1 levels far above than the body's typical production could lead to the system to generate a reduced amount of its own natural hormone, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.
"Discontinuation of this hormone supplement leads to appetite is uncontrolled, making excessive eating far more likely."
A Chronic Condition?
The NHS advise the jabs for people with weight-linked health risks, alongside prescribed lifestyle changes.
Professionals argue that, given the significant potential of weight regain, the treatment might need to be ongoing.
This opinion is echoed by drug manufacturers, who say that the findings "highlight the long-term nature of obesity," similar to managing diseases like diabetes.
User Testimonies
Users who have stopped the jabs explain a intense resurgence of hunger.
"I experienced a switch that goes on and you become extremely hungry," described a patient.
The struggle is exacerbated if patients have not established sustainable lifestyle or habit changes during therapy.
Widespread Use
Survey data show that a significant number of adults in the UK have used these injections in the past year, with interest continuing to grow.
- Use is higher among females than men.
- The 40s and 50s age group shows the greatest usage rates.
- A large proportion obtain the medications through private prescriptions rather than the NHS.
Ultimately, clinicians stress that while these medications are effective tools for weight loss, they are not a standalone fix and maintained weight loss likely depends on ongoing behavioural support.
